Skip to main content

GLYC

Stock
Health Care
Biotechnology

Performance overview

GLYC Price
Price Chart

Forward-looking statistics

Beta
2.04
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.

Company info

SectorHealth Care
IndustryBiotechnology
Employees44
Market cap$16.6M

Fundamentals

Enterprise value
Revenue
Revenue per employee
Profit margin
Debt to equity

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)
Dividend per share
Revenue per share
Avg trading volume (30 day)
Avg trading volume (10 day)
Put-call ratio

Macro factor sensitivity

Growth-3.1
Credit+5.0
Liquidity+4.3
Inflation-4.7
Commodities-3.0
Interest Rates-4.8

Valuation

Dividend yield0.00%
PEG Ratio
Price to sales
P/E Ratio-2.91
Enterprise Value to Revenue
Price to book

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day
Ex. dividend day

News

Should You Buy GlycoMimetics (GLYC) Ahead of Earnings?

GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research (March 21, 2024)
GlycoMimetics' Lead Candidate Data Published In An Online Journal

GlycoMimetics Inc (NASDAQ: GLYC) has announced that efficacy and safety data from a Phase 1/2 study of uproleselan were published online in the journal BLOOD.  In the manuscript, scientists highlighted an analysis of minimal residual disease (MRD).

Benzinga (September 24, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free